Caussé S, Bouquin R, Wylomanski S, Flamant M, Joubert M, Dréno B, Quéreux G. [Infliximab-induced hepatitis during treatment of vulvar Crohn's disease].
Ann Dermatol Venereol 2012;
140:46-51. [PMID:
23328360 DOI:
10.1016/j.annder.2012.10.601]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Revised: 12/06/2011] [Accepted: 10/31/2012] [Indexed: 02/08/2023]
Abstract
BACKGROUND
We report a case of acute cytolytic hepatitis induced by infliximab in a patient with severe vulvar Crohn's disease.
PATIENTS AND METHODS
A 29-year-old Congolese woman presented with severe vulvar Crohn's disease active for 7 years. In view of resistance to standard medication (corticosteroids and metronidazole), treatment with infliximab 5mg/kg per injection was initiated. The patient developed acute cytolytic hepatitis 10 days after the first injection and the disease was asymptomatic. The various investigations confirmed the direct cytotoxicity of infliximab. A favourable outcome was gradually achieved after increasing the dosage of corticosteroids. At the same time, an improvement in the vulvar lesions was noted after this sole injection.
DISCUSSION
Infliximab-induced is rare, with only 20 reported cases. The physiopathological mechanism is unknown and a number of aetiologies have been suggested.
CONCLUSION
This new case raises the issue of the need for routine liver function testing during infliximab therapy given the asymptomatic nature of this effect.
Collapse